At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 29 April 2022, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2021 and decided that no dividend for the financial year 2021 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...
A broader and stronger licensing business strengthens our position in infection prevention First quarter (January-March 2022) Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7%...
Bactiguard today entered an agreement to initiate a global development partnership with Dentsply Sirona in the dental field, a new application area for the Bactiguard technology. The initial development phase, which is expected to last approximately one year, can generate USD 0.9 million in development and milestone related revenues for...
The annual report for Bactiguard Holding AB (publ) 2021 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 29 and can be ordered by sending an email to: info@bactiguard.com. This information is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Friday, 29 April 2022. Due to the continued uncertainty about the Covid-19 pandemic, the Board of Directors has decided that the AGM will be conducted without physical...
Bactiguard Holding AB (publ) has appointed Carin Jakobson, who has many years of experience as CFO of listed companies and a background in the medtech and pharmaceutical industry, as Chief Financial Officer. Carin Jakobson, who is currently CFO of the Rolling Optics Group, will take up her new position at Bactiguard in June 2022 and report to...
In previous press releases regarding the year-end report for 2021, incorrect information related to "Cash flow from operating activities" has been reported. Correction is made with this press release and the correct PDF is attached for Bactiguard Holding AB's (publ) year-end report 2021. Investments for future sales growth impacted profitability...
Investments for future sales growth impacted profitability Fourth quarter (October-December 2021) Revenues amounted to SEK 46.1 (55.6) million, a decrease of 17%, primarily due to lower license revenue. Adjusted for currency effects revenues decreased by 22%. EBITDA amounted to SEK -12.1 (4.9) million with an EBITDA margin of -26% (9%). Operating...
Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least 1 billion SEK and annual EBITDA of at least 400 million SEK in 2026. "With Bactiguard's unique technology for infection prevention, scalable business...
Following the announcement of the expanded partnership with Zimmer Biomet, Bactiguard has decided to publish the year-end report for 2021 tonight at 23.00 CET, instead of on Thursday February 10, as earlier announced. An audiocasted presentation will take place on Wednesday February 9 at 15.00 CET. Bactiguard's CEO Anders Göransson and CFO...
Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. It includes license and...